EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated

Tanner J Freeman, Thomas J George, Samuel A Jacobs, Greg Yothers, Tatjana Kolevska, Huichen Feng, Corey Lipchik, Sai Maley, Nan Song, Ashok Srinivasan, Melanie Finnigan, James L Wade und 8 weitere

Cancer Chemotherapy and Pharmacology · 2025-12 · 95 (1)

DOI: 10.1007/s00280-025-04802-8 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 09.08.2025. Verfasst von Tanner J Freeman und 19 weiteren Autor:innen. Beteiligte Einrichtung: NSABP Foundation, Inc, Pittsburgh, PA, USA. Tanner.Freeman@NSABP.org. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: This work was supported in part by Puma Biotechnology, Inc, and the NSABP Foundation, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with single-agent cetuximab (C) or panitumumab (P), have improved progression-free survival (PFS) and overall survival (OS) compared to best supportive care but an objective response rate (ORR) of only 13-17%. Preclinical and clinical data suggest that dual targeted therapy (e.g., neratinib [N] + C) may improve overall response rates in tumors that are wt for KRAS, NRAS, BRAF, and PIK3CA (quadruple-wt). METHODS: NSABP FC-11 is a multi-center, two-arm, phase II study in patients with quadruple-wt mCRC who had prior oxaliplatin and irinotecan treatment. Arm 1 treated patients with HER2 mutation, with or without prior C or P. Arm 2 treated HER2 non-amplified (14 evaluable) and HER2-amplified (1 evaluable) patients with N + C. The primary aim was PFS at cycle 6 (PFS6). Secondary aims included ORR, objective response, clinical benefit, and safety. Exploratory aims included molecular profiling for mutations, copy number, and RNA expression. RESULTS: Arm 1 closed early due to low accrual (n = 4) and is not reported. Arm 2 enrolled 21 patients; six discontinued treatment before first scan. Fifteen patients were evaluable with at least one follow-up scan with six demonstrating PFS6. With intention-to-treat (ITT) analysis, this cohort demonstrated an ORR/PFS6 of 28% (6/21). No grade 5 or otherwise unexpected adverse events were noted. Correlative molecular studies did not definitively define responders. CONCLUSION: Arm 2 of FC-11 demonstrated an ORR/PFS6 of 28%, which compares favorably to single-agent treatment in this subset of patients. CLINICAL TRIALS REGISTRATION: NCT03457896.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansCetuximabFemaleErb-b2 Receptor Tyrosine KinasesMiddle AgedMaleAgedProto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins p21(ras)QuinolinesMutationTrastuzumabAdultGTP PhosphohydrolasesProgression-Free SurvivalAged, 80 and overMembrane ProteinsNeoplasm Metastasis

Stichwörter der Autor:innen

CetuximabHER2Metastatic colorectal cancerNeratinibTrastuzumab

Substanzen

CetuximabErb-b2 Receptor Tyrosine KinasesProto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins p21(ras)QuinolinesTrastuzumabGTP PhosphohydrolasesMembrane ProteinsERBB2 protein, human

Autor:innen und Institutionen

  • NSABP Foundation, Inc, Pittsburgh, PA, USA. Tanner.Freeman@NSABP.org.
  • University of Pittsburgh, Pittsburgh, PA, USA. Tanner.Freeman@NSABP.org.
  • NSABP Foundation, Inc, Pittsburgh, PA, USA.
  • The University of Florida Health Cancer Center, Gainesville, FL, USA.
  • University of Pittsburgh, Pittsburgh, PA, USA.
  • NSABP/NRG Oncology, Pittsburgh, PA, USA.

Förderung

  • This work was supported in part by Puma Biotechnology, Inc, and the NSABP Foundation, Inc.

Zitieren

APA

Freeman, T. J., George, T. J., Jacobs, S. A., Yothers, G., Kolevska, T., Feng, H., Lipchik, C., Maley, S., Song, N., Srinivasan, A., Finnigan, M., Wade, J. L., Buchschacher, G. L., Al Baghdadi, T., Shipstone, A., Lin, D., Puhalla, S. L., Allegra, C. J., Wolmark, N., & Pogue-Geile, K. L. (2025). NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated. Cancer Chemotherapy and Pharmacology, 95(1). https://doi.org/10.1007/s00280-025-04802-8

Vancouver

Freeman TJ, George TJ, Jacobs SA, Yothers G, Kolevska T, Feng H, et al. NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated. Cancer Chemotherapy and Pharmacology. 2025;95(1). doi:10.1007/s00280-025-04802-8

BibTeX
@article{Freeman2025,
  author = {Freeman, Tanner J and George, Thomas J and Jacobs, Samuel A and Yothers, Greg and Kolevska, Tatjana and Feng, Huichen and Lipchik, Corey and Maley, Sai and Song, Nan and Srinivasan, Ashok and Finnigan, Melanie and Wade, James L and Buchschacher, Gary L and Al Baghdadi, Tareq and Shipstone, Asheesh and Lin, Daniel and Puhalla, Shannon L and Allegra, Carmen J and Wolmark, Norman and Pogue-Geile, Katherine L},
  title = {NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  volume = {95},
  number = {1},
  doi = {10.1007/s00280-025-04802-8}
}
Kostenlos starten →